[Dalphaz-retard treatment of urination disorders in men and women].
Loran
O B
OB
Pushkar'
D Iu
DIu
Rasner
P I
PI
D000276:Adjuvants, Immunologic / Q000008:administration & dosage / Q000627:therapeutic use; D000317:Adrenergic alpha-Antagonists / Q000008:administration & dosage / Q000627:therapeutic use*; D000700:Analgesics / Q000008:administration & dosage / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D008297:Male; D010713:Phosphatidylcholines / Q000008:administration & dosage / Q000627:therapeutic use; D011470:Prostatic Hyperplasia / Q000150:complications; D011799:Quinazolines / Q000008:administration & dosage / Q000627:therapeutic use*; D012737:Sex Factors; D013997:Time Factors; D014555:Urination Disorders / Q000188:drug therapy* / Q000209:etiology; D005680:gamma-Aminobutyric Acid / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use
D000276:Adjuvants, Immunologic; D000317:Adrenergic alpha-Antagonists; D000700:Analgesics; D010713:Phosphatidylcholines; D011799:Quinazolines; C011246:essential 303 forte; C044905:nicotinoyl-GABA; D005680:gamma-Aminobutyric Acid; C047638:alfuzosin